Dr. Christian Gisselbrecht on Defining Refractory Disease in DLBCL

Christian Gisselbrecht, MD
Published: Saturday, Jun 11, 2016



Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses stratifying refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).
 
Instead of just assuming a patient is refractory because they’ve relapsed, Gisselbrecht’s team wanted a more precise definition.
 
In collaboration with several companies and cancer centers, Gisselbrecht’s team determined several types of refractory patients.
 
By defining different groups of relapsed patients, prognostic factors can be determined for specific populations, says Gisselbrecht.

<<< View more from the 2016 EHA Congress


Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses stratifying refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).
 
Instead of just assuming a patient is refractory because they’ve relapsed, Gisselbrecht’s team wanted a more precise definition.
 
In collaboration with several companies and cancer centers, Gisselbrecht’s team determined several types of refractory patients.
 
By defining different groups of relapsed patients, prognostic factors can be determined for specific populations, says Gisselbrecht.

<<< View more from the 2016 EHA Congress

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x